Clinical Trials Logo

Cervical Artery Dissection clinical trials

View clinical trials related to Cervical Artery Dissection.

Filter by:
  • None
  • Page 1

NCT ID: NCT06258109 Recruiting - Clinical trials for Pregnancy Complications

Risk of Recurrent CeAD After Pregnancy

LONG-RECAP
Start date: January 1, 2023
Phase:
Study type: Observational

Primary objective: To determine whether pregnancy increases the risk of recurrent CeAD and delayed stroke in women with prior CeAD based on long-term data. Methods: Multicentric, observational case-control study based on pooled individual patient data from several stroke centers. Primary endpoint: Primary composite outcome measure includes the following outcomes: (i) occurrence of recurrent CeAD, (ii) occurrence of ischemic or hemorrhagic stroke, (iii) death.

NCT ID: NCT04253535 Completed - Clinical trials for Cervical Artery Dissection

Risk of Recurrence of Cervical Artery Dissection During Pregnancy and Puerperium

Start date: February 14, 2020
Phase:
Study type: Observational

Cervical artery dissection (CAD) accounts for about 2% of all strokes, and is a major cause of stroke in young people (about 15%). Many cases of CAD during pregnancy and puerperium have been described, suggesting that pregnancy and puerperium may be potential risk factors for CAD. The purpose of this study is to determine whether pregnancy and puerperium are also recurrence risk factors for CAD.

NCT ID: NCT02046460 Completed - Clinical trials for Cervical Artery Dissection

Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD

TREAT-CAD
Start date: September 2013
Phase: Phase 3
Study type: Interventional

Primary objective: To demonstrate the non-inferiority of acetylsalicylic acid (ASA) to anticoagulant treatment (vitamin K antagonists) in CAD-patients with regard to outcome and complication measures. Methods: Randomized controlled, open labeled multicenter, non-inferiority trial with blinded assessment of outcome events. Primary endpoint: Primary composite outcome measure - labeled Cerebrovascular Ischemia, major Hemorrhagic events or Death (CIHD) - includes the following efficacy and safety outcome measures during the treatment period: (i) occurrence of any stroke*, new acute lesions on diffusion weighted MRI (ii) any major extracranial hemorrhage, any symptomatic intracranial hemorrhage and any asymptomatic micro- or macrobleeds, (iii) death.

NCT ID: NCT01967511 Recruiting - Clinical trials for Spontaneous Coronary Artery Dissection

Defining the Basis of Fibromuscular Dysplasia (FMD)

DEFINE
Start date: October 2013
Phase:
Study type: Observational

The purpose of this study has evolved and expanded since its inception. Originally the intent was to establish the functional, molecular and genetic profile of fibroblasts from Fibromuscular Dysplasia (FMD) patients as compared to carefully matched control subjects. While this remains among the objectives, the study has been expanded to undertake a fully powered cross-tissue systems genetics analysis of FMD, and now also the related arteriopathies spontaneous coronary artery dissection (SCAD) and cervical artery dissection (CvAD). The overall objective is to disclose the core biologic mechanisms of these disorders.

NCT ID: NCT00657969 Active, not recruiting - Stroke Clinical Trials

Looking For Genetic and Environmental Risk Factors and Therapeutic Aspects in Cervical Artery Dissections

CADISP
Start date: July 2005
Phase: N/A
Study type: Observational

The main purpose of this study is to look for genetic and environmental risk factors of cervical artery dissections, a major cause of ischemic stroke in young adults, in a large multicenter case-control trial

NCT ID: NCT00238667 Completed - Stroke Clinical Trials

To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection

CADISS
Start date: November 2005
Phase: Phase 3
Study type: Interventional

This is a feasibility study to determine if a sufficient number of patients can be recruited throughout the United Kingdom and whether sufficient endpoints can be generated for a full scale therapeutic trial of anticoagulants versus antiplatelets in acute cervical artery dissection treatment.